With the implementation of mammalian target of rapamycin (mTOR) inhibitors in the systemic treatment of advanced renal cell carcinoma (RCC), considerable progress has been made regarding survival time and quality of life (QoL) compared with the treatment options used earlier. The prognostic factors used and the diagnostic measures taken to evaluate the oncological outcome and QoL of affected patients have not been adapted to this development adequately. This study analyses the recent phase III mammalian target of rapamycin inhibition trials for patients with metastatic RCC focussing on parameters for measurement of efficacy and QoL. It emphasizes the importance of adequate evaluation criteria for survival and QoL, as achieved by quality adjusted-time without symptoms and toxicity, in the palliative setting of advanced RCC.
aDepartment of Urology, Lukas Hospital, Neuss
bWest German Cancer Center (WTZ), University of Essen, Essen
cGerman Center for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Germany
dMontefiore Medical Center, Department of Medical Oncology, The Albert Einstein Cancer Center, New York, USA
Correspondence to Dr Christoph Eimer, Department of Urology, Lukas Hospital, Preussen Strasse 84, 41464 Neuss, Germany Tel: +4921318882410; fax: +4921318882499; e-mail: CEimer@lukasneuss.de
Received June 12, 2010